Table 1. Patient and tumor characteristics vs. the pathology results of SLN.
| Characteristics | Total | SLN negative | SLN positive | P value |
|---|---|---|---|---|
| Age (years) | 51.67±10.00 | 49.70±9.25 | 51.95±10.90 | 0.299 |
| Tumor size (cm) | 2.25±0.83 | 2.05±0.85 | 2.45±0.69 | 0.020 |
| Menopause | 0.283 | |||
| No | 36 (40.9) | 18 (50.0) | 18 (50.0) | |
| Yes | 52 (59.1) | 32 (61.5) | 20 (38.5) | |
| Microcalcification | 0.087 | |||
| No | 53 (60.2) | 34 (64.2) | 19 (35.8) | |
| Yes | 35 (39.8) | 16 (45.7) | 19 (54.3) | |
| Blood flow grade | 0.028 | |||
| 0–1 | 19 (21.6) | 15 (78.9) | 4 (21.1) | |
| 2–3 | 84 (78.4) | 35 (50.7) | 34 (49.3) | |
| Molecular subtype | 0.650 | |||
| Luminal A | 32 (36.4) | 21 (65.6) | 11 (34.4) | |
| Luminal B | 23 (26.1) | 12 (52.2) | 11 (47.8) | |
| HER2 | 20 (22.7) | 10 (50.0) | 10 (50.0) | |
| Triple-negative | 13 (14.8) | 7 (53.8) | 6 (46.2) |
Data are shown as mean ± standard deviation or n (%). SLN, sentinel lymph node; HER2, human epidermal growth factor receptor 2.